These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10823804)

  • 1. Predictive value of genotypic and phenotypic resistance in 2 nelfinavir-experienced patients.
    Bakker A
    J Infect Dis; 2000 May; 181(5):1862-4. PubMed ID: 10823804
    [No Abstract]   [Full Text] [Related]  

  • 2. Phenotypic HIV-1 resistance correlates with treatment outcome of nelfinavir salvage therapy.
    Walter H; Schmidt B; Rascu A; Helm M; Moschik B; Paatz C; Kurowski M; Korn K; Uberla K; Harrer T
    Antivir Ther; 2000 Dec; 5(4):249-56. PubMed ID: 11142619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
    Atkinson B; Isaacson J; Knowles M; Mazabel E; Patick AK
    J Infect Dis; 2000 Aug; 182(2):420-7. PubMed ID: 10915071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance.
    de Mendoza C; Valer L; Bacheler L; Pattery T; Corral A; Soriano V
    AIDS; 2006 Apr; 20(7):1071-4. PubMed ID: 16603864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.
    Patick AK; Duran M; Cao Y; Shugarts D; Keller MR; Mazabel E; Knowles M; Chapman S; Kuritzkes DR; Markowitz M
    Antimicrob Agents Chemother; 1998 Oct; 42(10):2637-44. PubMed ID: 9756769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
    J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
    Ferrer E; Podzamczer D; Arnedo M; Fumero E; McKenna P; Rinehart A; Pérez JL; Barberá MJ; Pumarola T; Gatell JM; Gudiol F;
    J Infect Dis; 2003 Feb; 187(4):687-90. PubMed ID: 12599088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
    Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
    J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
    Demeter LM; Ribaudo HJ; Erice A; Eshleman SH; Hammer SM; Hellmann NS; Fischl MA;
    Clin Infect Dis; 2004 Aug; 39(4):552-8. PubMed ID: 15356820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor.
    Gianotti N; Tambussi G; Boeri E; Lazzarin A
    J Biol Regul Homeost Agents; 2001; 15(2):166-9. PubMed ID: 11501975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH; Petropoulos CJ; Ziermann R; Schleif WA; Shivaprakash M; Emini EA
    J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two possible pathways for acquisition of mutations related to nelfinavir resistance.
    Sugiura W; Oishi T; Okano A; Matsuda M; Abumi H; Yamada K; Koike M; Taki M; Ishikawa M; Miura T; Fukutake K; Gouchi K; Ajisawa A; Iwamoto A; Hanabusa H; Mimaya J; Takamatsu J; Takata N; Kakishita E; Higasa S; Kashiwagi S; Shirahata A; Nagai Y
    Jpn J Infect Dis; 1999 Aug; 52(4):175-6. PubMed ID: 10592904
    [No Abstract]   [Full Text] [Related]  

  • 14. Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.
    Roquebert B; Malet I; Wirden M; Tubiana R; Valantin MA; Simon A; Katlama C; Peytavin G; Calvez V; Marcelin AG
    AIDS; 2006 Jan; 20(2):287-9. PubMed ID: 16511425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nelfinavir (Viracept).
    Res Initiat Treat Action; 2000 Mar; 6(1):30-1. PubMed ID: 11708185
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug resistance mutations in HIV-1-infected subjects during protease inhibitor-containing highly active antiretroviral therapy with nelfinavir or indinavir.
    Yerly S; Rickenbach M; Popescu M; Taffe P; Craig C; Perrin L;
    Antivir Ther; 2001 Sep; 6(3):185-9. PubMed ID: 11808753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recall of AIDS drug hits world's poorest patients.
    AIDS Read; 2007 Sep; 17(9):439. PubMed ID: 17902224
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of human immunodeficiency virus type 1 subtype C on drug resistance mutations in patients from Botswana failing a nelfinavir-containing regimen.
    Doualla-Bell F; Avalos A; Gaolathe T; Mine M; Gaseitsiwe S; Ndwapi N; Novitsky VA; Brenner B; Oliveira M; Moisi D; Moffat H; Thior I; Essex M; Wainberg MA
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2210-3. PubMed ID: 16723586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characterization of resistance in HIV. Comparison of geno- and phenotypic resistance to HIV-1 protease inhibitors].
    Schmidt B; Walter H; Korn K
    Pharm Unserer Zeit; 2001; 30(3):228-32. PubMed ID: 11400672
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.